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Abstract
Aims/hypothesis We aimed to identifymicroRNAs (miRNAs)
associated with type 2 diabetes and risk of developing the
disease in skeletal muscle biopsies from phenotypically well-
characterised twins.
Methods Wemeasuredmuscle miRNA levels in monozygotic
(MZ) twins discordant for type 2 diabetes using arrays.
Further investigations of selected miRNAs included target
prediction, pathway analysis, silencing in cells and association
analyses in a separate cohort of 164 non-diabetic MZ and
dizygotic twins. The effects of elevated glucose and insulin
levels on miRNA expression were examined, and the effect of
low birthweight (LBW) was studied in rats.
Results We identified 20 miRNAs that were downregulated in
MZ twins with diabetes compared with their non-diabetic co-
twins. Differences for members of the miR-15 family (miR-15b
and miR-16) were the most statistically significant, and these
miRNAs were predicted to influence insulin signalling. Indeed,
miR-15b and miR-16 levels were associated with levels of key
insulin signalling proteins, miR-15b was associated with the
insulin receptor in non-diabetic twins and knockdown of miR-
15b/miR-16 in myocytes changed the levels of insulin signal-
ling proteins. LBW in twins and undernutrition during pregnan-
cy in rats were, in contrast to overt type 2 diabetes, associated
with increased expression of miR-15b and/or miR-16. Elevated
glucose and insulin suppressed miR-16 expression in vitro.
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Conclusions Type 2 diabetes is associated with non-genetic
downregulation of several miRNAs in skeletal muscle includ-
ing miR-15b and miR-16, potentially targeting insulin signal-
ling. The paradoxical findings in twins with overt diabetes and
twins at increased risk of the disease underscore the complex-
ity of the regulation of muscle insulin signalling in glucose
homeostasis.
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Abbreviations
DAVID Database for Annotation Visualization
and Integrated Discovery
DZ Dizygotic
FDR False-discovery rate
GIR Glucose infusion rate
IGT Impaired glucose tolerance
INSR Insulin receptor
IPA Ingenuity pathway analysis
LBW Low birthweight
Limma Linear models for microarray data
LNA Locked nucleic acid
LP Low protein
miRNA MicroRNA
mTOR Mechanistic target of rapamycin
(serine/threonine kinase)
MZ Monozygotic
NGT Normal glucose tolerance
PIK3R1 Phosphoinositide 3-kinase R1 regulatory
subunit 1 α
PI3K Phosphoinositide 3-kinase
Rd Glucose disposal rate
V˙O2max Maximal oxygen consumption rate
Introduction
Type 2 diabetes is caused by multiple organ defects, with
inadequate insulin secretion and insulin resistance being the
most important. Skeletal muscle insulin resistance is of spe-
cific interest as muscle is the major site for glucose disposal
[1]. The insulin signalling cascade is initiated by the binding
of insulin to its receptor, which activates the key cellular
processes of glucose metabolism, including glucose transport
across the membrane and storage of glucose as muscle glyco-
gen. Although the genetic influence on muscle insulin resis-
tance cannot be disputed [2], non-genetic factors, including
obesity, physical inactivity and low birthweight (LBW) [3–6],
are important in controlling muscle insulin resistance [7–9].
Emerging evidence points towards microRNAs (miRNAs)
as major players in the regulation of protein levels. These
miRNAs are short single-stranded RNA molecules that regu-
late their target mRNAs mainly by translational repression
and/or degradation [10]. We recently demonstrated that miR-
483-3p, involved in adipose tissue development and lipid
storage, is upregulated in adipose tissue from individuals born
with LBW as well as in young adult rats exposed to a sub-
optimal intrauterine environment [11]. Another recent study
indicated that several miRNAs were differentially expressed
in skeletal muscle from patients with type 2 diabetes [12], and
Zhu et al recently demonstrated that overexpression of the
miRNA let-7 results in insulin resistance and impaired glucose
tolerance in rats, probably through repression of proteins in
the insulin–phosphoinositide 3-kinase–mechanistic target of
rapamycin (insulin–PI3K–mTOR) pathway [13]. Thus,
miRNAs could therefore be important regulators of insulin
signalling.
We have previously provided extensive proof-of-concept
evidence for the powerful approach of using genetically identi-
cal monozygotic (MZ) twins discordant for type 2 diabetes to
identify non-genetic metabolic and molecular defects in type 2
diabetes [4, 14]. When unravelling the complex underlying
molecular mechanisms involved in the development of type 2
diabetes, it is important to distinguish between the primary
mechanisms relevant to the development of type 2 diabetes
and the secondary molecular alterations occurring as a conse-
quence of the metabolic derangements including ‘glucotoxicity’
in hyperglycaemic patients with overt type 2 diabetes.
In the present study, we first aimed to identify altered
miRNA levels of non-genetic origin in MZ twins discordant
for type 2 diabetes. The top candidates identified were subse-
quently investigated in a larger group of phenotypically well-
characterised twins without diabetes to uncover their role in
skeletal muscle insulin action. Our comprehensive approach
also included computational target prediction and in vitro
target validation using antagomirs, while the effects of elevat-
ed glucose and insulin levels onmiRNA expression level were
studied in vitro. Finally, we studied miRNA expression in a rat
model of LBW.
Methods
Participants
The MZ discordant twin population comprised 22 white MZ
twins (11 pairs), aged 53–78 years, discordant for type 2
diabetes who were recruited through the Danish Twin
Registry, University of Southern Denmark. Five pairs were
from a previous cohort [15–17] where discordance for type 2
diabetes was recognised based on an OGTT. The additional
six twin pairs were recruited based on their discordance for
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type 2 diabetes. The recruitment and clinical examinations of
all 11 pairs has been described previously [18]. The basic
clinical and anthropometric measures are presented in
Table 1. Based on a 2 h OGTT, nine of the non-diabetic co-
twins had impaired glucose tolerance (IGT) and two had
normal glucose tolerance (NGT).
The non-diabetic twin population was a subgroup of 164
MZ and same-sex dizygotic (DZ) twins (the number of indi-
viduals with available tissue material) from a previously de-
scribed population [7] of 196 young and old twins (aged 25–
32 and 58–66 years). Participant characteristics are displayed
in Table 1.
All study participants gave informed consent and the study
was carried out in accordance with the Declaration of Helsinki
as revised in 2008.
Clinical examination
In the MZ discordant twin population, insulin sensitivity was
measured by a 2 h euglycaemic–hyperinsulinaemic clamp
(40 mU m−2 min−1) and expressed as the mean glucose
infusion rate (GIR) during the final 30 min steady-state period
of the clamp. In the non-diabetic twin population, 3-3H-glu-
cose was infused for the calculation of the peripheral glucose
disposal rate (Rd), and body composition was determined by
dual-energy x-ray absorptiometry (DXA) scanning. A 2 h 75 g
OGTT was performed in both populations and muscle biop-
sies (vastus lateralis) were excised under local anaesthesia
(lidocaine), during basal fasting conditions using a
Bergström needle with suction applied. The biopsies were
frozen immediately in liquid nitrogen and stored at −80°C
for later analysis. In the non-diabetic twin population, physical
fitness was estimated as maximal oxygen consumption rate
(V˙O2max) calculated from the maximal load on ergometer
bicycle [19]. More details can be found in previous publica-
tions of this cohort [7, 15–18].
LNA arrays
For each of the discordant twins (n=22), 1 μg total RNAwas
isolated from a muscle biopsy (described in electronic supple-
mentarymaterial [ESM]methods) and each sample was run on
a miRCURY locked nucleic acid (LNA) array (Exiqon,
Vedbaek, Denmark) representing version 9.2 of the Sanger
miRBase as described in the ESM Methods. Annotation was
updated to miRBase version 14, and the data were normalised
using normexp [20] and quantile normalisation [21] in R
(version 2.9.1). The dataset has been deposited in the
National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus [22], accession number GSE38835.
Familiar relationships and target analysis
The familiar relationships between miRNAs were based on
miRBase version 17. TargetScan 4.2 [23–25] was used to
predict mRNA targets. The lists of targets were imported into
Ingenuity pathway analysis (IPA) version 8.0 (IPA, QIAGEN,
Redwood City, www.qiagen.com/ingenuity) for canonical
pathway analysis or the Database for Annotation,
Visualization and Integrated Discovery (DAVID) 6.2. for a
Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
way analysis [26]. The IPA results were corrected for multiple
testing using the Benjamini–Hochberg method.
Table 1 Clinical and metabolic
characteristics of the study
populations
Data are represented asmean±SD
a n=9 in each group; b n=10 in
each group
FFM, fat-free mass; Glu120,
120 min glucose values from an
OGTT
Characteristic Discordant monozygotic twin study Non-diabetic
twin study
Diabetic twins Non-diabetic
co-twins
p value
n (female/male) 11 (6/5) 11 (6/5) 164 (76/88)
n (NGT/IGT/T2D) 11 (0/0/11) 11 (2/9/0) —
Zygosity (MZ/DZ) — — 90/74
Age (years) 68±8 68±8 42.9±17.1
Birthweight (g) — — 2,671±468
BMI (kg/m2) 32.5±6.7 30.4±6.5 0.04 25.3±4
Fasting glucose (mmol/l) 10.6±2.1 6.3±0.5 <0.001 5.4±0.7
Glu120 (mmol/l) 19.5±3.5 9.0±1.7 <0.0001 6.5±1.7
GIR (mg m−2 min−1)a 153.8±63.2 288.1±175.4 0.05 —
HbA1c (%)
b 7.7±1.5 5.9±0.5 <0.003 —
HbA1c (mmol/mol) 61±16.4 41±5.5 —
Total fat (%) — — 24.7±9
Rd (mg kgFFM
−1min−1) — — 10.9±3.4
V˙O2max (ml kg
−2 min−1) — — 33.9±10.1
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Statistical methods
Differential expression levels in the discordant twins were
assessed using a paired design matrix with linear models for
microarray data (Limma) [27, 28] in R. Spot quality weights
[29] were used and p values were adjusted with Benjamini–
Hochberg’s false-discovery rate (FDR) [30]. Limma was used
to analyse 170 miRNAs in a published online dataset [12] for
differences between those with NGT, IGT and type 2 diabetes.
Pearson intra-pair correlation coefficients were calculated using
2n, as previously recommended [31]. The SAS ‘proc mixed’
procedure (SAS Institute, Cary, NC, USA) was used to perform
multiple regression analysis with adjustments for zygosity and
twin-pair status. If not otherwise stated, additional adjustment
for age, sex, V˙O2max, birthweight and total body fat percentage
was performed. GraphPad Prism (GraphPad Software, La Jolla,
CA, USA) was used to perform ANOVA.
Human myocytes
AntagomiR experiment Proliferating myoblasts from five
healthy donors (three men and two women) aged 59±7 years
were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) with 10 nmol/l antagomiRs (Exiqon)
targeting miR-15b/miR-16 or a non-targeting antagomiR
(Exiqon) for 48 h. Simultaneous knockdown of miR-15b
and miR-16 was performed to hinder a possible rescue effect
that could occur when inhibiting them separately. Cells were
harvested after 5–10min incubation with 0, 1, 10 or 100 nmol/
l insulin (Actrapid, Novo Nordisk, Bagsværd, Denmark) in
Trizol (Invitrogen) for RNA isolation or in lysis buffer (Cell
Signaling Technology, Beverly, MA, USA) for protein isola-
tion. See the ESM Methods for further details.
Short-term insulin experiment See the ESM Methods for the
description of this experiment.
Rat protocol
Adult females were fed ad libitum with either a control diet
(20% protein) or an isoenergetic low-protein (LP) (8% pro-
tein) diet (Arie Blok, Woerden, the Netherlands) during ges-
tation and lactation as described previously [32]. At 3 months
of age, 11 control males and 11 males from LP litters, each of
the 22 rats being from an independent litter, were killed and
vastus lateralis muscle biopsies were excised and stored for
later use. All animal procedures were approved by the local
animal ethical review committee and were carried out under
compliance with the UK Animal (Scientific Procedures) Act
1986. The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication no. 85–23, revised
1996). See the ESM Methods for further details.
L6 cells
L6 myoblasts were obtained from the American Type Culture
Collection (CRL-1458, ATCC) and cultured in DMEM
(Sigma-Aldrich, Poole, UK) with 10% fetal bovine serum,
penicillin (100 units/ml), streptomycin (100 mg/ml) and glu-
tamine (0.2 mmol/l), as previously described [33]. Semi-
confluent cultures were treated with four different combina-
tions of insulin (Actrapid; Novo Nordisk Insulin, Bagsværd,
Denmark) and glucose levels, 0 nmol/l insulin and 5.6 mmol/l
glucose, 100 nmol/l insulin and 5.6 mmol/l glucose, 0 nmol/l
insulin and 25 mmol/l glucose or 100 nmol/l insulin and
25 mmol/l glucose, every 24 h for a total of 96 h until
harvesting.
Gene expression
RNA isolation This is described in the RNA isolation section
of the ESM Methods. ABI-PRISM 7900 Sequence Detection
system ([ABI] Applied Biosystems, Foster City, CA, USA)
was used for both miRNA and mRNA detection. Expression
was quantified using TaqMan probes for miRNA and primers
from ABI or the Roche Universal probe library for mRNA.
Details are described in the ESM Methods.
Protein levels
Muscle cell cultures Levels of phosphoinositide 3-kinase R1
regulatory subunit 1 α (PIK3R1), Akt and p-Akt were mea-
sured using western blotting (Invitrogen). Insulin receptor
(INSR) levels were measured using Meso Scale Discovery
analysis (Meso Scale Discovery, Rockville, MD, USA).
Muscle biopsies The protein levels of INSR, IRS-1 and
PIK3R1 were measured using western blotting as described
in [2, 34]. Details of these methods are described in the
ESM Methods.
Results
Differentially expressed miRNAs in MZ twins discordant
for type 2 diabetes
To identifymiRNAs related to type 2 diabetes in a non-genetic
manner, we studied 571 human miRNAs in skeletal muscle
from 11 pairs of MZ twins discordant for type 2 diabetes. The
clinical and metabolic characteristics of these twins are
summarised in Table 1. Twenty miRNAs were identified as
significantly downregulated after correction for multiple com-
parisons ( pFDR<0.1) in twins with type 2 diabetes compared
with their corresponding non-diabetic co-twins (Table 2). No
miRNAs were significantly upregulated in the type 2 diabetes
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twins. No difference in the total miRNA expression levels
were found between the diabetic twins and their non-diabetic
co-twins when the medians of the log2 transformed raw ex-
pression values were compared using a paired t test ( p=0.25).
Box and density plots are shown in ESM Figs 1 and 2,
respectively. Intra-pair correlations between miRNA expres-
sion and HbA1c showed that ten of the 20 identified miRNAs,
including miR-15b, were negatively correlated with HbA1c
levels. Of these miR-15b, miR-451 and miR-363 remained
significant after FDR correction for multiple comparisons
( pFDR<0.1) (Table 2). Similar intra-pair correlations showed
that miR-15b alone was significantly negatively correlated
with the 2 h post-OGTT glucose values. This result was not
significant after FDR correction ( pFDR=0.2) (Table 2).
The diabetes-dysregulated miR-15 family is involved
in insulin signalling
The 20 identified miRNAs belong to 11 different miRNA
families (ESM Table 1); miRNAs within the same family are
predicted to target the samemRNAs. As shown in Table 2, the
top-rankingmiRNAs according to statistical significance were
miR-15b and miR-16. These both belong to the miR-15
family. The human miR-15 family consists of miR-15a,
miR-15b, miR-16 and miR-195 (Fig. 1a), in addition miR-
497 shares the seed sequence nucleotides 2–8. In humans,
miR-15b and miR-16 originate from the same transcriptional
cluster on chromosome 3 in the intron of SMC4, which
encodes structural maintenance of chromosomes 4. In addi-
tion, miR-16 is transcribed from chromosome 13, where it is
situated in the non-protein-coding region DLEU2 (deleted in
lymphocytic leukaemia 2) clustered together with miR-15a.
TargetScan predicts 968 conserved mRNA targets for the
miR-15 family, and analysing these targets using IPA showed
a total of 20 pathways that contained significantly higher
numbers of the predicted miR-15 family targets than expected
by chance ( pFDR<0.05) (Table 3). Among these, the insulin
signalling pathway had the most significant over-
representation of miR-15 family targets ( pFDR=0.004)
(Fig. 1b and Table 3). This pathway analysis finding was
confirmed using DAVID software, which was also used to
perform additional pathway analyses on the predicted
mRNA targets for each of the ten other miRNA families
(ESM Table 1).
Table 2 Differentially expressed miRNAs in skeletal muscle biopsies from genetically identical twins with type 2 diabetes when compared with their
non-diabetic co-twins
miRNA Family C FC p p(FDR) rGlu120 p-rGlu120 rHbA1c
p-rHbA1c
hsa-miR-15b miR-15 a −2.0 2.4×10−8 8.0×10−6 −0.64 0.04 −0.77 0.01
hsa-miR-16 miR-15 a −1.7 5.7×10−6 9.4×10−4 −0.41 0.21 −0.63 0.05
hsa-miR-17 miR-17 b −1.7 7.3×10−5 0.007 −0.53 0.1 −0.66 0.04
hsa-miR-451 −1.8 9.0×10−5 0.007 −0.55 0.08 −0.76 0.01
hsa-miR-106b miR-17 c −1.5 2.2×10−4 0.01 −0.57 0.07 −0.64 0.05
hsa-miR-103 miR-103 −1.5 5.3×10−4 0.03 −0.4 0.1 −0.67 0.03
hsa-miR-425 −1.6 6.2×10−4 0.03 −0.52 0.22 −0.52 0.12
hsa-miR-106a miR-17 d −1.7 8.9×10−4 0.04 −0.52 0.1 −0.67 0.03
hsa-miR-10b −1.5 1.0×10−3 0.04 0.1 0.77 −0.1 0.77
hsa-miR-25 miR-25 c −1.7 1.3×10−3 0.04 −0.4 0.11 −0.64 0.05
hsa-miR-93 miR-17 c −1.5 1.5×10−3 0.04 −0.51 0.23 −0.55 0.1
hsa-miR-363 d −1.7 1.6×10−3 0.04 −0.43 0.19 −0.76 0.01
hsa-miR-107 miR-103 −1.6 1.8×10−3 0.05 −0.56 0.07 −0.57 0.08
hsa-miR-191 −1.4 1.9×10−3 0.05 −0.56 0.07 −0.56 0.09
hsa-miR-30e* −1.6 2.2×10−3 0.05 −0.2 0.56 −0.1 0.78
hsa-let-7i −1.4 3.2×10−3 0.07 −0.25 0.46 −0.37 0.3
hsa-miR-20a miR-17 b −1.7 3.4×10−3 0.07 −0.41 0.2 −0.52 0.12
hsa-miR-223 −1.6 4.1×10−3 0.08 −0.55 0.08 −0.65 0.04
hsa-miR-92a miR-25 bd −1.4 4.9×10−3 0.09 −0.54 0.04 −0.59 0.08
hsa-miR-20b miR-17 d −1.5 5.6×10−3 0.09 −0.39 0.21 −0.61 0.06
The miR family names from miRBase demonstrate the relatedness between the miRNAs
Letters in ‘C’ show which miRNAs are from the same transcriptional cluster
FC, fold change; p(FDR), p values adjusted with Benjamini–Hochberg’s false-discovery rate; rGlu120, intra-pair correlation coefficient between miRNA
expression and 120 min OGTT glucose values; rHbA1c, intra-pair correlation coefficient between miRNA expression and HbA1c values; p-rHbA1c and p-r
Glu120, the p values for the intra-pair correlation analyses
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miR-15b and miR-16 regulate protein levels of insulin
signalling molecules
Three prominent players of the insulin signalling pathway
(INSR, IRS1 and PIK3R1) were among the predicted miR-
15b/-16 targets. To address the role of miR-15b and miR-16 in
the control of insulin signalling proteins, we measured the
protein and mRNA expression levels of these three predicted
targets in muscle biopsies from the non-diabetic twin
population.
We found miR-15b levels negatively associated with both
INSR and IRS-1 but not with PIK3R1 protein levels when
adjusted for confounding factors (Table 4). For miR-16, no
significant associations with the levels of these proteins were
observed. IRS1 mRNA levels was negatively associated with
miR-15b, but not with miR-16. No significant associations
between miR-15b or miR-16 and the mRNA levels of INSR
and PIK3R1 were found (Table 4). Adjustments for fasting
glucose levels and 2 h glucose values did not change any of
the results.
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG 22
hsa-miR-195-5p UAGCAGCACAGAAAUAUUGGC– 21
hsa-miR-15b-5p UAGCAGCACAUCAUGGUUUACA 22
hsa-miR-15a-5p UAGCAGCACAUAAUGGUUUGUG 22
*********   *   **
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Fig. 1 ThemiR-15 family and its targets in the INSR signalling pathway.
(a) Alignment of the nucleotide sequences of the human miR-15 family
members using CLUSTAL 2.0.12. Asterisks indicate conserved residues.
(b) The INSR signalling pathway. Grey nodes indicate predicted targets
of the miR-15 family (tuberous sclerosis 1 [TSC1], Raf-1 proto-oncogene,
serine/threonine kinase [RAF1], serum/glucocorticoid regulated kinase 1
[SGK1], thyroid hormone receptor interactor 10 [TRIP10], v-crk avian
sarcoma virus CT10 oncogene homolog-like [CRKL], PIK3R1, protein
kinase, cAMP-dependent, regulatory, type II, α [PRKAR2A], lipase,
hormone-sensitive [LIPE], protein phosphatase 1, regulatory [inhibitor]
subunit 11 [PPP1R11], eukaryotic translation initiation factor 2B, subunit
2 β, 39 kDa [eIF2B2], eukaryotic translation initiation factor 4E [eIF4E],
growth factor receptor-bound protein 10 [GRB10], forkhead box O1
[FOXO1], IRS1, son of sevenless homolog 1 [Drosophila] [SOS1],
eukaryotic translation initiation factor 2B, subunit 5 ε, 82 kDa [EIF2B5],
Akt3, IRS2, INSR and mitogen-activated protein kinase kinase 1
[MAP2K1]. Additional information on the nodes in the pathway can be
found in ESM Table 2. ER, endoplasmic reticulum
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To study the potential regulation of INSR and PIK3R1
protein and mRNA levels by miR-15b and miR-16, we
transfected antisense inhibitors specific to these miRNAs into
human primary myocytes, with insulin added 5–10 min prior
to harvest. Using ANOVA models we found no general effect
of insulin on protein levels and no interaction effects. We
observed a general increase in the total INSR protein content
following miR-15b/miR-16 inhibition ( p=0.01) and a general
downregulation of PIK3R1 protein levels in response to miR-
15b/16 inhibition ( p=0.0002) (ESM Fig. 3). The result on
PIK3R1 was in line with the borderline positive association
found between PIK3R1 protein levels and miR-16 in the non-
diabetic twins. AsmiR-15b andmiR-16 target multiple insulin
signalling molecules (Fig. 1b), it is relevant to study the
collective effect of their inhibition; to this end, we measured
the levels of p-Akt/Akt after miR-15b/miR-16 inhibition
(ESM Fig. 4). We did not observe any effect of miR-15b
and miR-16 inhibition on p-Akt/Akt levels. However, this
result was considered inconclusive due to large variations in
the p-Akt measurements.
Effects of high glucose and insulin levels on miRNA
expressions in cell culture
Elevated glucose and insulin levels defining a diabetogenic
environment might regulate miR-15b and miR-16. Short-term
incubation of cultured humanmyocytes with 10 nmol/l insulin
for 5, 10, 30, 60 or 120 min did not affect miR-15b or miR-16
levels (data not shown). We also tested the effect of high
glucose and high insulin levels in L6 cells (a rat myoblast cell
line) using a higher insulin concentration (100 nmol/l) with or
without high glucose (high 25 mmol/l, low 5.6 mmol/l) for a
prolonged time period of 96 h. Although the effects of high
glucose ( p=0.2) and high insulin levels ( p=0.2) on miR-15b
expression did not reach statistical significance in these cells
(Fig. 2a), we found that high insulin ( p=0.01) and high
glucose ( p=0.003) levels reduced the miR-16 levels (Fig. 2b).
Implications for intrauterine-dependent regulation
of the miR-15 family
To further explore the potential reasons for dysregulation of
the miR-15 family in type 2 diabetes, we measured the ex-
pression levels of miR-15b and miR-16 in the non-diabetic
twins. In this cohort, we found no associations between miR-
Table 3 Pathway analysis of the miR-15 family targets
Ingenuity canonical pathways p(FDR)
INSR signalling 0.0039
AMPK signalling 0.0045
PPARα/RXRα activation 0.0045
TGF-β signalling 0.0068
Wnt/β-catenin signalling 0.0126
IGF-1 signalling 0.0126
Molecular mechanisms of cancer 0.0126
mTOR signalling 0.0126
EIF2 signalling 0.0126
PI3K/Akt signalling 0.0126
BMP signalling pathway 0.0155
14-3-3-mediated signalling 0.0158
PTEN signalling 0.0245
Protein ubiquitination pathway 0.0339
Cell cycle regulation by BTG family proteins 0.0339
Axonal guidance signalling 0.0339
Ceramide signalling 0.0339
Mitotic roles of polo-like kinase 0.0355
Myc-mediated apoptosis signalling 0.0417
Cell cycle: G1/S checkpoint regulation 0.0417
IPA of the miR-15 family target genes predicted using TargetScan. Only
pathways with p(FDR) <0.05 are shown
AMPK, protein kinase, AMP-activated, alpha 1 catalytic subunit; BMP,
bone morphogenetic protein; BTG, B-cell translocation gene; EIF2,
eukaryotic translation initiation factor 2; p(FDR), Benjamini–Hochberg’s
multiple comparison adjusted p values; PPARα/RXRα, peroxisome
proliferator-activated receptor α/retinoid X receptor α; PTEN, phospha-
tase and tensin homologue; WNT, wingless-type MMTV integration site
family
Table 4 Impact of miR-15b and miR-16 on specific molecular targets in
the 164 non-diabetic twins
Target Effect CI 95% Change p
INSR protein
miR-15b 0.91 (0.86, 0.97) 9%↓ 0.004
miR-16 0.93 (0.86, 1.00) 7%↓ 0.06
INSR mRNA
miR-15b 0.94 (0.87, 1.02) 0.1
miR-16 1.00 (0.92, 1.09) 1.0
IRS-1 protein
miR-15b 0.82 (0.75, 0.88) 18%↓ <0.0001
miR-16 0.95 (0.87, 1.03) 0.2
IRS-1 mRNA
miR-15b 0.92 (0.86, 0.99) 8%↓ 0.03
miR-16 0.95 (0.88, 1.02) 0.2
PIK3R1 protein
miR-15b 0.97 (0.93, 1.02) 0.2
miR-16 1.04 (1.00, 1.08) 4%↑ 0.07
PIK3R1 mRNA
miR-15b 0.92 (0.85, 1.01) 8%↓ 0.07
miR-16 0.98 (0.90, 1.07) 0.6
Multivariate analysis of the effects of miR-15b or miR-16 on target
mRNA and protein expression with adjustment for age, sex, total fat
percentage, V˙O2max, birthweight, twin-pair and zygosity status
Effect, the effect on the response variable expressed as the change by 1
SD increase in either miR-15b or miR-16
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15b and miR-16 levels on one side and insulin action (Rd
clamp) or the 2 h post-OGTT glucose values on the other (data
not shown). Interestingly, multiple regression analysis showed
a negative association between birthweight and both miR-15b
and miR-16 expression levels (Table 5). Total body fat per-
centage was positively associated with miR-16 but not miR-
15b expression. Age, sex or V˙O2maxvalues were not associated
with miR-15b or miR-16 expression levels (Table 5). To study
further the effect of a poor intrauterine environment on the
expression of miR-15b and miR-16, we studied muscle tissue
from 3-month-old male rat offspring from dams fed either an
LP or a control diet [35, 36]. The LP offspring had lower body
weights both at day 3 after birth ( p=0.004) and at 3 months of
age ( p<0.0001). Elevated miR-15b levels were found in the
muscle of LP offspring ( p<0.001) (Fig. 3a), whereas the
levels of miR-16 were similar in the two groups (Fig. 3b).
Discussion
In a unique cohort of 11 MZ twin pairs discordant for type 2
diabetes, we identified 20 miRNAs that were differentially
expressed in the skeletal muscle of twins with type 2 diabetes
compared with their non-diabetic identical twins. In silico
analyses identified the two most significantly downregulated
miRNAs in twins with diabetes, miR-15b and miR-16, as
possible regulators of important metabolic functions including
insulin signalling. The predicted insulin signalling targets of
miR-15b and miR-16 included INSR, IRS-1 and PIK3R1, for
which we demonstrated a likely biological role in vivo (for
INSR and IRS-1) and in vitro (for INSR and p85). We found a
significant positive association between LBW and both miR-
15b and miR-16 in non-diabetic twins and elevated miR-15b
levels in a rat model of LBW. Finally, we showed a downreg-
ulation of miR-16 by high glucose and insulin levels in cell
cultures.
Interestingly, all of the 20 differentially expressed miRNAs
in the MZ twins with overt type 2 diabetes were downregu-
lated compared with their genetically identical twins, most of
whom had IGT. In support of this we found eight of the 20
miRNAs, including miR-15b and miR-16, to be downregulat-
ed in singletons with overt type 2 diabetes when we compared
their levels to those in singletons with IGT using an online
dataset [12]. Differences between these studies may be ex-
plained by the selective identification of non-genetic differ-
ences in discordant MZ twins.
Diabetes is defined by the presence of hyperglycaemia, and
we therefore tested the correlation between average glycaemic
levels (HbA1c) and the expression levels of each of the 20
miRNAs. Although only three of these miRNAs, including
miR-15b, showed a significant negative correlation with
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Fig. 2 The effect of high insulin and high glucose on miR-15b and miR-
16 expression levels in L6 cells. Levels of miR-15b (a) and miR-16 (b)
were measured in L6 cells after 96 h of stimulation with either low
glucose and no insulin, high glucose no insulin, low glucose with high
insulin or high glucose with high insulin. Data are mean±SD, n=3.
p values from two-way ANOVA: †p=0.02 for interaction effect, ‡‡p=
0.01 for insulin effect, §§§p=0.003 for glucose effect. AU, arbitrary
expression unit; LG, low glucose (5.6 mmol/l); HG, high glucose
(25 mmol/l)
Table 5 Factors associated with the expression of either miR-15b or
miR-16 in skeletal muscle obtained from the non-diabetic twins
Effect 95% CI Change p
miR-15b
Age 0.97 (0.72, 1.28) 0.8
Sex 0.81 (0.62, 1.05) 0.1
V˙O2max 0.99 (0.88, 1.11) 0.9
Birthweight 0.87 (0.79, 0.96) 13%↓ 0.005
Total fat percentage 1.11 (0.93, 1.34) 0.3
miR-16
Age 1.28 (0.99, 1.64) 0.06
Sex 1.06 (0.83, 1.35) 0.6
V˙O2max 1.08 (0.97, 1.19) 0.2
Birthweight 0.87 (0.80, 0.95) 13%↓ 0.002
Total fat percentage 1.27 (1.08, 1.48) 27%↑ 0.003
The effects of age, sex, V˙O2max, birthweight, and total body fat percentage
on the expression of either miR-15b or miR-16, investigated by multiple
regression analyses adjusted for twin-pair and zygosity status
Effect, the effect on the response variable expressed as the change by 1
SD increase in either miR-15b or miR-16
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Fig. 3 The effect of maternal protein restriction on skeletal muscle
expression levels of miR-15b and miR-16 in rats. miR-15b (a) and
miR-16 (b) expression levels were measured in vastus lateralis muscle
biopsies from 3-month-old male offspring of dams fed with low protein
(n=11) and control dams (n=11). Data are mean±SD. ***p<0.001 for
the effect of LP from two-sided unpaired t tests. AU, arbitrary expression
unit; LP, low protein
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HbA1c level after correction for multiple testing, we found the
same trend for all the 20 miRNAs, suggesting that
hyperglycaemia may be involved in the coordinated down-
regulation of miRNAs in twins with overt diabetes. Whether
this downregulation represents, for example, secondary po-
tentially deleterious changes due to hyperglycaemia, or plays
a role in the compensation for insulin resistance via
hyperglycaemia-induced glucose uptake [37] remains to be
investigated.
A previous study in pancreatic beta cells showed upregu-
lated miR-15a levels after hyperglycaemic exposure for 1 h,
with subsequent downregulation after 3 days of exposure [38].
We found that long-term exposure to elevated insulin and
glucose levels was associated with a downregulation of
miR-16 but not miR-15b in L6 cells, which suggests differ-
ential regulation. Acute insulin stimulation for up to 120 min
in human myocytes using a concentration of 10 nmol/l did not
show any effect, supporting previous in vivo clamp results in
humans [39].
Based on the presence of complementary binding sites for
the miR-15 family in the 3′UTR of mRNAs, we predicted
insulin signalling proteins including INSR, IRS-1 and
PIK3R1 to represent important targets for miR-15b and
miR-16. Indeed, our experiments in human myocytes showed
that the levels of INSR and PIK3R1 protein were altered
following inhibition of miR-15b/miR-16. INSR was upregu-
lated, indicating that miR-15b/miR-16 represses INSR trans-
lation, whereas PIK3R1 was downregulated, indicating en-
hanced translation. Both miRNA-mediated down- [10] and
upregulation [40, 41] of translation have previously been
described. Increased PIK3R1 levels were previously reported
to be associated with insulin resistance [42, 43], thus elevated
miR-15b and miR-16 levels could contribute to insulin resis-
tance through downregulation of INSR and a parallel upreg-
ulation of PIK3R1. The biological relevance of our results was
demonstrated in the non-diabetic twins, with a negative asso-
ciation between levels of miR-15b and INSR, a borderline
significant positive association between miR-16 and PIK3R1
and a highly significant negative association between
miR-15b and IRS-1 protein levels. 3′UTR luciferase stud-
ies could be instrumental in providing more insights into
the extent to which miR-15b and miR-16 bind to the 3′
UTR regions of their predicted targets, and to determine
the extent to which these miRNAs—alone or in concert
with other miRNAs—may influence the expression of one
or more insulin signalling proteins. Given the complex and
unknown interactions of miR-15b and miR-16 with many
other miRNAs, including the 20 miRNA we found down-
regulated in type 2 diabetes, such experiments will need to
be addressed in future papers.
There are multiple routes via which the insulin signal
travels [44, 45], and the predicted targets of miR-15b and
miR-16 suggest several that could be interesting. Here, we
tested downstream signalling through p-Akt/Akt but reached
no clear conclusion; thus, further studies will be needed to
determine the specific route of action for these miRNAs as
well as to determine their role in the other pathways contain-
ing their targets, several of which are known or suspected to
influence glucose metabolism. We did not find any significant
correlations between levels of miR-15b and miR-16 and
in vivo peripheral insulin resistance in the non-diabetic twins.
This may suggest that the absolute muscle expression level of
these miRNAs plays only a minor role in the control of in vivo
whole-body insulin action or that the potential effects need
unmasking by adverse ‘diabetogenic’ lifestyle conditions.
In our large cohort of non-diabetic twins, we observed a
negative association between birthweight and miR-15b and
miR-16 levels, which was further supported by elevated miR-
15b levels in an LBW rat model. The lack of significantly
elevated miR-16 levels in the rat model could reflect interspe-
cies differences in the regulation of the two clusters from
which the miR-15 family are transcribed. The upregulation
of miR-15b and miR-16 in twins with LBW, and the opposing
downregulation in the MZ twins with diabetes, is to some
extent paradoxical as LBW is associated with increased risk of
developing type 2 diabetes. It suggests differential regulation
as well as a potential impact of miR-15b and miR-16 at
different stages in the life-long development of type 2 diabe-
tes. This is supported by the finding of upregulated miR-15b
and miR-16 levels in individuals with IGT when compared
with both individuals with NGTand those with type 2 diabetes
in an independent online dataset [12]. In addition, we previ-
ously reported a similar differential regulation of insulin sig-
nalling genes in patients with overt type 2 diabetes compared
with their first-degree relatives which, similar to individuals
with IGT and individuals born with LBW, have an increased
risk of developing T2D [46]. Whether an adverse intrauterine
environment directly alters miR-15b and miR-16 levels and
the extent to which these miRNAs play a role in the develop-
ment of insulin resistance in individuals with an increased risk
of developing type 2 diabetes or whether they perhaps work to
counteract the enhanced activity in the insulin signalling path-
way that we have previously observed in insulin-resistant
individuals [47] remains to be disclosed by future studies.
In conclusion, we identified 20 downregulated miRNAs
including miR-15b and miR-16 in twins with overt type 2
diabetes compared with their genetically identical non-
diabetic co-twins. In a larger cohort of non-diabetic twins,
LBW was somewhat paradoxically associated with upregula-
tion of miR-15b and miR-16 levels. Our results indicate that
miR-15b and miR-16 may regulate key insulin signalling
protein levels. Additional studies are needed to understand
not only the role of the miR-15 family in the development of
insulin resistance and type 2 diabetes, but also the distinct or
interactive roles of the additional 18 downregulated miRNAs
in type 2 diabetes.
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